- Home
- VRAX vs TXMD Comparison
VRAX vs TXMD Comparison
Compare VRAX & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRAX | TXMD |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3M | 24.4M |
| IPO Year | 2021 | 2012 |
Fundamental Metrics
Financial Performance| Metric | VRAX | TXMD |
|---|---|---|
| Price | $2.76 | $2.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 65.5K | 17.8K |
| Earning Date | 06-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 73.68 |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $1,761,000.00 |
| Revenue This Year | $217,274.83 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $100.50 |
| Revenue Growth | N/A | ★ 35.25 |
| 52 Week Low | $0.10 | $0.99 |
| 52 Week High | $13.19 | $2.95 |
Technical Indicators
Market Signals| Indicator | VRAX | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 48.51 | 42.74 |
| Support Level | $2.55 | $1.97 |
| Resistance Level | $3.10 | $2.11 |
| Average True Range (ATR) | 0.18 | 0.05 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 42.61 | 5.58 |
Price Performance
Historical ComparisonAbout VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.